Edward P. O'Brien, J.D.
Chairman

Y. Jennifer Ahn, Pharm.D.
Executive Officer

Panel Members

Patrick R. Finley, Pharm.D.
Donald M. Hilty, M.D.
Andrew S. Kayser, MD, PhD
John E. Mendelson, M.D.
Laurence R. Upjohn, Pharm.D.

RESEARCH ADVISORY PANEL OF CALIFORNIA

455 Golden Gate Avenue, Suite 11000
San Francisco, CA 94102-7004
(415) 703-1373 / FAX: 703-1234
www.ag.ca.gov/research
jennifer.ahn@doj.ca.gov

December 15, 2014

Amy Emerson
MAPS Director of Clinical Research
1215 Mission Street
Santa Cruz, CA 95060

Dear Ms. Emerson:

Re: **PR#1424C** - "A Randomized, Double-Blind, Placebo-Controlled Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness"
(MDA-1)

Having reviewed the response, Panel hereby grants its approval. All conditions of Panel approval which are included in this letter must be observed.

The Panel does not require separate applications and approvals for the individual sites that will be conducting this multicenter clinical drug trial protocol in California. However, each site should be forwarded a copy of this approval letter, as documentation that this protocol has been reviewed and approved by the Panel is required to be on file at each site.

GENERAL CONDITIONS OF PANEL APPROVAL

- The California Research Subjects' Bill of Rights will be presented - at the onset of the consenting process - to every California subject participating in this study.
- The Panel requires that it be notified of any significant study drug related adverse effects (SAEs) that may emerge during conduction of this study at the California sites only via PDF only.
- The Panel will require notification of any amendments made to this protocol during the course of this study via PDF only (substantive changes may require re-review by the Panel).
- The Panel will also require that an annual progress report (or final closing report) on the status of this study be forwarded to the Panel office via PDF only, informing the Panel of the sites and number of subjects participating in the study in California; any significant occurrences that may have taken place during conduction of the study; and concluding with a general summary of the progress or outcome of the study. Please refer to our website for the detailed instruction.

The Panel extends its best wishes in the undertaking of this clinical drug trial in California.

Sincerely,

Edward P. O'Brien, J.D.
Chairman

Y. Jennifer Ahn

Y. Jennifer Ahn, Pharm.D.
Executive Officer